Clinical Trial ImbalanceThere were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.
Management ChangesThe recent management changes including transition of the roles of CEO, CFO, and Chief Legal Officer moving into consulting roles as the company evaluates strategic alternatives.
Study Endpoint MissThe previously announced primary endpoint miss for the Phase 2B ASPIRE study comparing UBX1325 and aflibercept in diabetic macular edema patients, not achieving non-inferiority at the average of weeks 20 and 24 primary analysis.